PI3K/Akt/mTOR信号通路在急性淋巴细胞白血病中的靶向治疗现状  

Status of PI3K/Akt/mTOR Signaling Pathway in Targeted Therapy for Acute Lymphoblastic Leukemia

作　　者：赖定财 毕丽伟 许雅苹 陈广怡 LAI Dingcai;BI Liwei;XU Yaping;CHEN Guangyi(Department of Pharmacy,Xiamen Medical College,Xiamen 361023,China;Department of Basic Medicine,Xiamen Medical College,Xiamen 361023,China;Xiamen Key Laboratory of Traditional Chinese Medicine Bioengineering,Xiamen 361023,China)

机构地区：[1]厦门医学院药学系,福建厦门361023 [2]厦门医学院基础医学部,福建厦门361023 [3]厦门市中药生物工程重点实验室,福建厦门361023

出　　处：《医学综述》2024年第11期1286-1291,共6页Medical Recapitulate

基　　金：福建省自然科学基金面上项目(2023J011658);厦门市自然科学基金联合项目(3502Z202374041);厦门医学院科研课题(K2021-01)。

摘　　要：磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/Akt/mTOR)信号通路广泛参与细胞中多种生命活动进程,是导致癌症产生的重要细胞内信号通路。尽管当前急性淋巴细胞白血病(ALL)的治疗方案已有所改善,但仍有一些患者预后不良。因此,探索靶向抑制PI3K/Akt/mTOR信号通路的药物对治疗ALL具有重要意义。目前对于靶向抑制PI3K/Akt/mTOR信号通路的药物研究发展迅速,但仍存在选择性低、易产生耐药性等问题。未来通过对PI3K/Akt/mTOR信号通路在ALL发生发展过程中作用机制的深入研究与联合靶向治疗等方案的探索,有望为ALL的靶向治疗提供新思路,以改善患者预后。The phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin(PI3K/Akt/mTOR)signaling pathway is widely involved in various cellular life processes and is a significant intracellular signaling pathway leading to cancer development.Although the current treatment regimen for acute lymphoblastic leukemia(ALL)has improved,some patients still have poor prognosis.Therefore,exploring drugs targeting the inhibition of the PI3K/Akt/mTOR signaling pathway for the treatment of ALL is of great significance.The current research and development of drugs targeting the PI3K/Akt/mTOR signaling pathway have progressed rapidly,but issues such as low selectivity and the susceptibility to drug resistance still remain.In the future,in-depth studies on the mechanisms of PI3K/Akt/mTOR signaling pathway in the occurrence and progression of ALL,together with the exploration of combined targeted therapies,are expected to provide new ideas for the targeted treatment of ALL to improve the patient prognosis.

关 键 词：急性淋巴细胞白血病 磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路 靶向治疗 

分 类 号：R733.71[医药卫生—肿瘤]